Tags

Type your tag names separated by a space and hit enter

Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%.
Allergy Asthma Proc. 2008 Nov-Dec; 29(6):659-68.AA

Abstract

Allergic rhinitis is a chronic, allergen-induced inflammatory reaction. Patients often differentiate intranasal treatments based on sensory attributes. The purpose of this study was to evaluate the sensory attributes of olopatadine HCl nasal spray 0.6% (OLO) relative to azelastine HCl nasal spray 0.1% (AZE). This was a multicenter, double-blind, randomized, crossover comparison of OLO versus AZE in adult, symptomatic patients with at least a 2-year history of allergic rhinitis. Patients received each of the treatments separately with a washout between exposures, evaluated their sensory perceptions immediately after and 45 minutes postdosing with each treatment, and evaluated their perceptions of the two medications after administering both therapies. The mean age of the 110 patients was 42.4 years; 67% were women. OLO was superior to AZE in overall aftertaste (60.6% versus 30.3%; p = 0.0005), patient preference (62.4% versus 33.9%; p = 0.0001), and likelihood of extended use (60.9% versus 34.5%; p = 0.0004). OLO was superior to AZE in perceptions of immediate taste (1.9 U versus 3.2 U, respectively; p < 0.0001). Perceptions of additional attributes after administration of both treatments were significant and favored OLO (p < or = 0.0036 for all variables). In these assessments, respectively, 54.1 and 32.1% of patients favored the taste and smell of OLO compared with 27.5 and 11.9% who favored AZE. Both treatments were well tolerated. The sensory attributes of OLO are superior to AZE in terms of immediate taste postdosing, overall aftertaste, overall patient preference, and likelihood of use. This outcome could lead to greater patient compliance and improved treatment effect.

Authors+Show Affiliations

Allergy and Asthma Medical Group and Research Center, San Diego, CA 92123, USA. eomeltzer@aol.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19144261

Citation

Meltzer, Eli O., et al. "Comparative Study of Sensory Attributes of Two Antihistamine Nasal Sprays: Olopatadine 0.6% and Azelastine 0.1%." Allergy and Asthma Proceedings, vol. 29, no. 6, 2008, pp. 659-68.
Meltzer EO, Garadi R, Laforce C, et al. Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc. 2008;29(6):659-68.
Meltzer, E. O., Garadi, R., Laforce, C., Chadwick, S. J., Berger, W. E., Gross, G., Edwards, M. R., Crenshaw, K., & Wall, G. M. (2008). Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. Allergy and Asthma Proceedings, 29(6), 659-68. https://doi.org/10.2500/aap.2008.29.3181
Meltzer EO, et al. Comparative Study of Sensory Attributes of Two Antihistamine Nasal Sprays: Olopatadine 0.6% and Azelastine 0.1%. Allergy Asthma Proc. 2008 Nov-Dec;29(6):659-68. PubMed PMID: 19144261.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. AU - Meltzer,Eli O, AU - Garadi,Rekha, AU - Laforce,Craig, AU - Chadwick,Stephen J, AU - Berger,William E, AU - Gross,Gary, AU - Edwards,Michael R, AU - Crenshaw,Krista, AU - Wall,G Michael, Y1 - 2008/12/06/ PY - 2009/1/16/entrez PY - 2009/1/16/pubmed PY - 2009/3/10/medline SP - 659 EP - 68 JF - Allergy and asthma proceedings JO - Allergy Asthma Proc VL - 29 IS - 6 N2 - Allergic rhinitis is a chronic, allergen-induced inflammatory reaction. Patients often differentiate intranasal treatments based on sensory attributes. The purpose of this study was to evaluate the sensory attributes of olopatadine HCl nasal spray 0.6% (OLO) relative to azelastine HCl nasal spray 0.1% (AZE). This was a multicenter, double-blind, randomized, crossover comparison of OLO versus AZE in adult, symptomatic patients with at least a 2-year history of allergic rhinitis. Patients received each of the treatments separately with a washout between exposures, evaluated their sensory perceptions immediately after and 45 minutes postdosing with each treatment, and evaluated their perceptions of the two medications after administering both therapies. The mean age of the 110 patients was 42.4 years; 67% were women. OLO was superior to AZE in overall aftertaste (60.6% versus 30.3%; p = 0.0005), patient preference (62.4% versus 33.9%; p = 0.0001), and likelihood of extended use (60.9% versus 34.5%; p = 0.0004). OLO was superior to AZE in perceptions of immediate taste (1.9 U versus 3.2 U, respectively; p < 0.0001). Perceptions of additional attributes after administration of both treatments were significant and favored OLO (p < or = 0.0036 for all variables). In these assessments, respectively, 54.1 and 32.1% of patients favored the taste and smell of OLO compared with 27.5 and 11.9% who favored AZE. Both treatments were well tolerated. The sensory attributes of OLO are superior to AZE in terms of immediate taste postdosing, overall aftertaste, overall patient preference, and likelihood of use. This outcome could lead to greater patient compliance and improved treatment effect. SN - 1088-5412 UR - https://www.unboundmedicine.com/medline/citation/19144261/Comparative_study_of_sensory_attributes_of_two_antihistamine_nasal_sprays:_olopatadine_0_6_and_azelastine_0_1_ L2 - https://www.ingentaconnect.com/openurl?genre=article&amp;issn=1088-5412&amp;volume=29&amp;issue=6&amp;spage=659&amp;aulast=Meltzer DB - PRIME DP - Unbound Medicine ER -